16 completed, 7 terminated, 1 unknown. 24 Phase 2, 9 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 16, Terminated 7, Unknown 1 |
| Phase 1 | 9 | Completed 7, Terminated 2 |
| Phase 3 | 2 | Terminated 1, Unknown 1 |
Follow oblimersen: new trials by email Literature Review of oblimersen trials Research Report on oblimersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma Genasense, Paclitaxel, Carboplatin - Melanoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2010-12-01 | 2016-02-11 |
| Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma oblimersen sodium, rituximab, laboratory biomarker analysis - Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 52 | 2006-03-01 | 2013-01-07 |
| Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery oblimersen sodium, imatinib mesylate, laboratory biomarker analysis - Gastrointestinal Stromal Tumor | Phase 2 | Terminated | National Cancer Institute (NCI) | 96 | 2005-09-01 | 2013-06-05 |
| Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment Genasense® (G3139, oblimersen sodium) - Advanced Melanoma and Normal or Impaired, Hepatic Function | Phase 2 / Phase 3 | Terminated | Genta Incorporated | 6 | 2005-08-01 | 2011-11-07 |
| Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma oblimersen sodium, rituximab, ifosfamide - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2004-05-01 | 2013-01-24 |
| Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate oblimersen sodium, docetaxel - Prostate Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 116 | 2004-04-01 | 2012-09-24 |
| S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma oblimersen sodium, rituximab, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 160 | 2004-03-01 | 2013-01-07 |
| Oblimersen in Treating Patients With Merkel Cell Carcinoma oblimersen sodium, pharmacological study, laboratory biomarker analysis - Recurrent Neuroendocrine Carcinoma of the Skin, Stage I Neuroendocrine Carcinoma of the Skin | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2004-01-01 | 2013-06-04 |
| Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer recombinant interferon alfa, oblimersen sodium, pharmacological study - Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2003-08-01 | 2013-08-26 |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer oblimersen sodium, cisplatin, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2003-06-01 | 2021-02-17 |
| Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer oblimersen sodium, doxorubicin hydrochloride, docetaxel - Male Breast Cancer, Stage IIIA Breast Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 31 | 2003-05-01 | 2019-03-05 |
| Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia oblimersen sodium - Waldenström Macroglobulinemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 58 | 2003-05-01 | 2013-06-04 |
| Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer oblimersen sodium, carboplatin, etoposide - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2003-04-01 | 2013-01-14 |
| Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma oblimersen sodium, rituximab, laboratory biomarker analysis - Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2003-01-01 | 2014-05-28 |
| Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia oblimersen sodium, imatinib mesylate, laboratory biomarker analysis - Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2002-11-01 | 2013-06-04 |
| Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) oblimersen sodium, doxorubicin hydrochloride - Liver Cancer | Phase 2 | Completed | University Health Network, Toronto | 27 | 2002-10-01 | 2017-11-08 |
| Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer oblimersen sodium, fluorouracil, leucovorin calcium - Colorectal Cancer | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 16 | 2002-10-01 | 2012-07-04 |
| Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma oblimersen sodium, dexamethasone, thalidomide - Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Completed | University of Maryland, Baltimore | 2002-09-01 | 2019-10-17 | |
| Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer oblimersen sodium, docetaxel - Lung Cancer | Phase 2 / Phase 3 | Unknown | Genta Incorporated | 2001-10-01 | 2014-01-06 | |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia Oblimerson sodium, G3139 - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Completed | Genta Incorporated | 40 | 2001-01-01 | 2009-11-13 |
Showing 20 of 24. Sign in to see all of them.
Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Rectal Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Esophageal Neoplasms (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Mantle-Cell (2) · Prostatic Neoplasms (2) · Small Cell Lung Carcinoma (2)
National Cancer Institute (NCI) (12) · Genta Incorporated (4) · The University of Texas Health Science Center at San Antonio (2) · European Organisation for Research and Treatment of Cancer - EORTC (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · University Health Network, Toronto (1) · University of Chicago (1) · University of Maryland, Baltimore (1)
United States (21) · Canada (2) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Portugal (1) · Russia (1) · Spain (1) · United Kingdom (1)
Anthony W. Tolcher, MD (2) · Andreas Kaubisch (1) · Ashraf Z. Badros, MD (1) · Barbara Grant (1) · Barbara Pro (1) · Charles M. Rudin, MD, PhD (1) · Cora N. Sternberg, MD, FACP (1) · Deborah Braccia (1) · Francisco Esteva (1) · Jennifer Knox, MD (1) · Jonathan Trent (1) · Ki Chung (1) · Kim Margolin (1) · Meir Wetzler (1) · Michael Morris, MD (1)
PMID 12056703, PMID 15867202, PMID 16186597, PMID 16730060, PMID 18060598, PMID 19297314, PMID 19738454
U10CA031946 (3), N01CM17003 (2), N01CM62202 (2), N01CM17101 (1), N01CM17104 (1), N01CM17107 (1), N01CM62201 (1), N01CM62203 (1), N01CM62204 (1), N01CM62206 (1), N01CM62207 (1), P30CA016672 (1), P30CA054174 (1), U01CA069853 (1), U10CA032102 (1)